We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Finger Stick Blood Test Detects Early Signs of Heart Attack Before it Occurs

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: Micro-device designed to sense blood clots could pick up early signs of heart attack (Photo courtesy of Pexels)
Image: Micro-device designed to sense blood clots could pick up early signs of heart attack (Photo courtesy of Pexels)

Heart attacks and strokes are the world’s leading cause of death. Many are caused by blood clots that block the flow of blood to the heart, often in at-risk individuals without any physical warning. However, long before a heart attack or stroke occurs, tiny changes in the blood begin taking place. Often, blood flow is disturbed, leading to blood clotting and inflammation which can block blood vessels. Now, researchers are developing a biomedical micro-device to detect these subtle platelet changes before a heart attack or stroke takes place.

Using a pin-prick test, the micro-device developed by scientists at the University of Sydney (Sydney, Australia) would take a blood sample from a person’s finger. The sample would then be analyzed for platelet clotting and white cell inflammation responses, information that would be immediately processed by an external operating system. The scientists will undertake further engineering development for the microdevice, which is predicated on an integrated microfluidic chip. The team is also working to build highly sensitive computational fluid dynamics simulations to better understand the impact of mechanical forces that could lead to blood pooling and clots.

“How this device would work is that an at-risk person, for example, someone with heart disease, would use it daily. Using a finger prick test, the device would monitor their blood and alert them to any potentially dangerous changes. If a change was detected, they would need to present for more monitoring at a hospital," said Dr. Arnold Lining Ju, an award-winning biomedical engineer from the University of Sydney's Nano Institute and School of Biomedical Engineering.

Research assistant Laura Moldovan said that, historically, it has been difficult to predict when a heart attack or stroke might happen: “They appear to occur at random, sometimes without any physical symptoms, however in fact there are tiny physical changes that occur in the blood – the key to this device is being able to sensitively monitor these microscopic changes.”

Related Links:
University of Sydney 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.